


Product data sheet



MedKoo Cat#: 200080 Name: Aderbasib CAS#: 791828-58-5 Chemical Formula: C ₂₁ H ₂₈ N ₄ O ₅ Exact Mass: 416.20597	
Product supplied as:	Powder
Purity (by HPLC):	≥ 98%
Shipping conditions	Ambient temperature
Storage conditions:	Powder: -20°C 3 years; 4°C 2 years. In solvent: -80°C 3 months; -20°C 2 weeks.

1. Product description:

Aderbasib, also known as INCB007839, is a sheddase inhibitor, is also an orally bioavailable inhibitor of the ADAM (A Disintegrin And Metalloprotease) family of multifunctional membrane-bound proteins with potential antineoplastic activity. Aderbasib represses the metalloproteinase "shedase" activities of ADAM10 and ADAM17, which may result in the inhibition of tumor cell proliferation. The metalloproteinase domains of ADAMs cleave cell surface proteins at extracellular sites proximal to the cell membrane, releasing or "shedding" soluble protein ectodomains from the cell surface; the disintegrin domains of these multifunctional proteins interact with various components of the extracellular matrix (ECM).

2. CoA, QC data, SDS, and handling instruction

SDS and handling instruction, CoA with copies of QC data (NMR, HPLC and MS analytical spectra) can be downloaded from the product web page under "QC And Documents" section. Note: copies of analytical spectra may not be available if the product is being supplied by MedKoo partners. Whether the product was made by MedKoo or provided by its partners, the quality is 100% guaranteed.

3. Solubility data

Solvent	Max Conc. mg/mL	Max Conc. mM
DMSO	100.0	240.11

4. Stock solution preparation table:

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	2.40 mL	12.01 mL	24.01 mL
5 mM	0.48 mL	2.40 mL	4.80 mL
10 mM	0.24 mL	1.20 mL	2.40 mL
50 mM	0.05 mL	0.24 mL	0.48 mL

5. Molarity Calculator, Reconstitution Calculator, Dilution Calculator

Please refer the product web page under section of "Calculator"

6. Recommended literature which reported protocols for in vitro and in vivo study

In vitro study

TBD

In vivo study

1. Witters L, Scherle P, Friedman S, Fridman J, Caulder E, Newton R, Lipton A. Synergistic inhibition with a dual epidermal growth factor receptor/HER-2/neu tyrosine kinase inhibitor and a disintegrin and metalloprotease inhibitor. *Cancer Res.* 2008 Sep 1;68(17):7083-9. doi: 10.1158/0008-5472.CAN-08-0739. PMID: 18757423.

7. Bioactivity

Biological target:

Aderbasib (INCB007839) is a potent, orally active and target specific low nanomolar hydroxamate-based inhibitor of ADAM10 and ADAM17 that exhibits robust antineoplastic activity.

In vitro activity

TBD

Product data sheet



In vivo activity

HER-2/neu+ BT474-SC1 human breast cancer xenografts were established. INCB7839 was administered at a dose capable of achieving steady-state levels of 500 nmol/L to 1 μ mol/L in plasma. This concentration was previously determined to be above the IC50 for HER-2/neu and EGFR ligand shedding. Treatment with the INCB7839 sheddase inhibitor resulted in a decrease in mean tumor volume compared with animals treated with the vehicle.

Reference: Cancer Res. 2008 Sep 1;68(17):7083-9. <https://cancerres.aacrjournals.org/content/68/17/7083.long>

Note: The information listed here was extracted from literature. MedKoo has not independently retested and confirmed the accuracy of these methods. Customer should use it just for a reference only.